GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Tax Provision

HBM Holdings (HKSE:02142) Tax Provision : HK$-2.0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Tax Provision?

HBM Holdings's tax provision for the six months ended in Jun. 2024 was HK$-2.6 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-2.0 Mil.


HBM Holdings Tax Provision Historical Data

The historical data trend for HBM Holdings's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Tax Provision Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Provision
Get a 7-Day Free Trial 0.72 0.77 -0.38 -1.93 0.63

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.80 -0.15 0.09 0.55 -2.55

HBM Holdings Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HBM Holdings Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
Executives
Wang Jingsong 2101 Beneficial owner
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Owap Investment Pte Ltd 2101 Beneficial owner
Gic Special Investments Private Limited 2102 Investment manager
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
South Dakota Trust Company Llc 2301 Trustee
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Pang Kee Chan Hebert
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you
Morgan Stanley & Co. International Plc 2105 Underwriter
Advantech Capital Holdings Ltd.
Harbourbio Llc 2101 Beneficial owner

HBM Holdings Headlines

No Headlines